How Databricks leveraged a16z to get its first big enterprise customers and go from $1M to $7B ARR in 10 years: "a16z is a little special. They have relationships with the CIOs of some of the biggest enterprises on the planet. They'd invite the CIO of a company like Apple or Capital One in for a Silicon Valley Day, and show them ten portfolio companies. We'd get thirty minutes to demo. The mistake startups make is sending a junior salesperson. I did most of those myself. I get to pitch my product to the CIO of a huge company. And most of the time, they're so thankful you took the time that they'll give you a POC or a small land. Now you're in the door, with a big logo. So go pitch those yourself. 'Can you intro me to XYZ' is less valuable. I'd rather target fewer companies where I can actually add value. We landed a bunch of our biggest customers that way."

Today, for the first time, an FDA advisory panel voted to open a legal path for BPC-157 — the most sought-after peptide in the world. That's genuinely a milestone. And it's worth understanding exactly what just happened. The panel voted 8-6 to recommend adding BPC-157 to the list of substances licensed compounding pharmacies can prepare under a real prescription. FDA staff had recommended against it. The panel went the other way. Here's why I think that matters, even as a cautious physician. Right now, millions of people are already taking this. They're buying research-grade powder from anonymous overseas sellers, mixing it on a kitchen counter, and injecting it. Over 40% of gray-market samples fail purity testing. No dosing standards. No sterility guarantee. No adverse-event reporting. No physician watching. A vote like today's is the first real step toward moving all of that into daylight — into licensed pharmacies, with quality control, physician oversight, and traceable safety data. That's a genuine win for patient safety, regardless of what you believe about the molecule. And the underlying science is legitimately exciting. BPC-157 is a synthetic peptide modeled on a protective protein found in human gastric juice. Hundreds of animal studies show accelerated tendon and ligament healing, gut protection, anti-inflammatory effects, and angiogenesis — the growth of new blood vessels. The preclinical signal is strong enough that serious researchers keep coming back to it. That's not nothing. That's why the demand exists in the first place. Now the sober part, because you deserve both halves. The published human evidence is still remarkably thin — roughly 30 subjects in the strongest studies, with the longest treatment lasting about two weeks. And the routes actually studied barely overlap with how people use it today. There are no completed randomized controlled trials for the popular uses. Also worth knowing: today's vote is not FDA approval. It's advisory and non-binding. Formal rulemaking takes 12 to 24 months. Nothing changed legally today. My one clinical caution, and it comes from my own field: the same angiogenesis that may heal a tendon is a signal that says grow. Nobody has studied that over years, and nobody has studied it in cancer survivors. Worth a real conversation with your doctor before you assume it's harmless. But here's the encouraging part. A Phase 2 hamstring trial is already underway. A regulated pathway means better product, real prescriptions, and — crucially — actual data collection instead of anecdotes. This is how a gray market becomes medicine: oversight first, then evidence, then answers. Today was a step in that direction. Now let's get the trials done and find out what this thing can really do.

✨ a-nation 2026 — Tickets On Sale Now!! The legendary music festival returns to Tokyo Odaiba for the first time in 23 years! Two days of non-stop energy and unforgettable performances 🔥💿 📍 Venue: Odaiba a-nation Special Stage, Tokyo 🗓 Dates: October 3 (Sat) & 4 (Sun), 2026 🕒 Time: Doors 12:00 / Show 13:00 (tentative) （UCT+9） 🎤【Lineup】 ■Oct 3: EXILE / Bullet Train / CHANYEOL / Strawberry Prince / WINNER / NCT JNJM / NCT WISH & more… ■Oct 4: Ayumi Hamasaki / J.Y. Park / Da-iCE / TRF / JUN. K / AK-69 / FANTASTICS & more… Click to secure your spots! ✨ a-nation 2026 チケット発売中！！ 23年ぶりに東京・お台場へ戻ってくる、秋の大人気音楽フェス🔥 超豪華アーティストが2日間にわたり、ステージを熱狂の渦に変える💿⚡️ 📍 会場：東京・お台場 a-nation 特設会場 🗓 日程：2026年10月3日（土）・4日（日） 🕒 時間：開場 12:00 / 開演 13:00（予定）（UCT+9） 🎤【出演アーティスト】 ■10/3：EXILE / 超特急 / CHANYEOL / すとぷり / WINNER / NCT JNJM / NCT WISH ほか… ■10/4：浜崎あゆみ / J.Y. Park / Da-iCE / TRF / JUN. K / AK-69 / FANTASTICS ほか… 👉チケットはこちら： #a_nation2026# #お台場# #EXILE# #浜崎あゆみ# #音楽フェス#

As #trade# tensions between #China# and the European Union show signs of escalating, economists and executives are calling on Brussels to abandon its "de-risking" strategy, strengthen dialogue with Beijing and enhance its competitiveness and supply chain resilience through deeper cooperation — a move they say would provide much-needed certainty for the global economy. #EU# #economy#

Hey algorithm, Show this to anyone tired of juggling ten apps and just wants everything in one place: - Crypto - Equities - Perps - Prediction Markets - Futures - Earning Yield - Lending - Borrowing - Spending - Payments - Portfolio Tracking - Commodities - Metals Thanks, The On-Chain Super App.

Canada plans to show some of the world’s biggest investors a pitchbook laying out tens of billions of dollars worth of projects spanning data centers, advanced manufacturing, liquefied natural gas, ports and dozens of mines, per Bloomberg